| 摘要 |
The present invention is directed to the targeting of cytotoxic immunological effector cells, such as human macrophages and lymphokine activated killer (LAK) cells, to tumors, such as colon adenocarcinomas, their metastases, and other diseased tissues, which selectively express specific cell surface antigens. The targeting of the effector cells is accomplished by binding to them antibodies which are specific for the selectively expressed antigens of the tumors or other diseased tissues. The invention is also directed to the process of producing these targeted, cytotoxic effector cells, and to the targeted, cytotoxic effector cells themselves. The invention is also directed to uses for these targeted effector cells including their in vivo use to suppress the growth of, to kill, and their in vivo and in vitro use to diagnostically image tumor and other diseased animal cells in humans and other animals. |
